"It is really fantastic that we are continuing our collaboration with the research team at KI, which is a brilliant team with many years of experience in bacteriological research and vaccine development. Their contribution will undoubtedly be of great importance for our ongoing vaccine development projects" says Dr. Andrew Waller Chief Scientific Officer at Intervacc.

"We are very satisfied with the results that our research groups at KI and SLU have achieved and look forward to continued successful collaboration through this extended agreement," says Jonas Sohlman, CEO at Intervacc AB.

Intervacc's research pipeline, in addition to Strangvac, includes two vaccine projects. One project against Streptococcus suis infections in piglets and a second project against Staphylococcus aureus infections in dairy cows, which results in intractable mastitis. Streptococcus suis causes severe infections in pig herds with devastating results for the pig industry. There are almost one billion pigs worldwide and a safe and efficacious vaccine is long awaited.

Efficacious vaccines against these common infections are an important tool for enhancing animal health and welfare, improving the economics of food production and reducing the use of antibiotics. Vaccine development is also a crucial tool for reducing the widespread problem of resistance to antibiotics which is a global threat of great concern.

Professor Birgitta Henriques Normark at Karolinska Institutet said, "I'm very pleased with the cooperation with Intervacc and we are excited to continue our work together with the development team. Together we are a leader in developing vaccines using recombinant fusion proteins and recombinant vaccine technologies. This agreement confirms Intervacc and KI's long-term commitment to the project."

For more information please contact:

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600, Cell: +46 (0) 70 576 30 73

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on August 15, 2024, 09.30 a.m. CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company's vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Sciences where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.

About Karolinska Institutet

Karolinska Institutet is one of the world's leading medical universities. Its vision is to significantly contribute to the improvement of human health. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine. Visit the website at http://www.ki.se

About SLU the Swedish University of Agricultural Sciences

SLU, the Swedish University of Agricultural Sciences, is a world-class international university with research, education and environmental assessment within the sciences for sustainable life. Its principal sites are in Alnarp, Umeå and Uppsala, but activities are also conducted at research stations, experimental parks and educational establishments throughout Sweden. We bring together people who have different perspectives, but they all have one and the same goal: to create the best conditions for a sustainable, thriving and better world. Please visit the website http://www.slu.se/ for more information.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se,Phone: +46 (0)8 - 684 211 10